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Background: There is no information in the literature on the impact of changes in quality of life (QoL) scores on
prognosis in ovarian cancer. We investigated whether changes in QoL during treatment could predict survival in
ovarian cancer patients.
Methods: We evaluated 137 ovarian cancer patients treated at our institution between Jan 2001 and Dec 2009
who were available for a minimum follow-up of 3 months. QoL was evaluated at baseline and after 3 months of
treatment using EORTC-QLQ-C30. Cox regression evaluated the prognostic significance of baseline and changes in
QoL scores after adjusting for clinical and demographic variables.
Results: Associations between changes in QoL and survival were observed for global function, appetite loss and
constipation. Every 10-point increase (improvement) in global function from baseline to 3 months was associated
with a 10% decreased risk of death (HR=0.90; 95% CI: 0.81 to 0.99, p=0.03). The corresponding HRs for 10-point
increase (deterioration) in appetite loss and constipation scales were 1.20 (95% CI: 1.06 to 1.35; p=0.005) and 1.13
(95% CI: 1.02 to 1.24; p=0.02) respectively.
Conclusions: This exploratory study provides evidence that an improvement in appetite, constipation and global
health scores during the first 3 months of treatment is significantly associated with improved survival time in
ovarian cancer. These findings justify serial, systematic assessment of global health, appetite and constipation in
ovarian cancer patients being treated, and suggest that modalities designed to improve these functions may be
beneficial clinically.Background
With an incidence of about 26,000 cases per year, ovar-
ian cancer is the second most common gynecologic ma-
lignancy and the leading cause of mortality from
gynecologic cancers in the USA, resulting in approxi-
mately 14,500 deaths annually [1]. Most women are di-
agnosed as having advanced stage disease and undergo
aggressive debulking surgery and primary postoperative
chemotherapy, and yet the majority experience recur-
rence [2-4]. Tumor stage, age, performance status,
tumor histology, and residual tumor are some of the
independent predictors of survival in patients with ovar-
ian cancer [5].* Correspondence: digant.gupta@ctca-hope.com
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reproduction in any medium, provided the orGiven that ovarian cancer and its treatment can cause
significant physical and psychological morbidity [3], as-
sessment of quality of life (QoL) is particularly important
for these patients [6-10]. It is important to focus not
only on the short-term side effects of treatment, but also
on the effects of treatment on symptoms and functional
status during periods of disease remission, relapse, and
survival. Such effects not only influence a patient’s over-
all QoL, they also influence the ability to tolerate add-
itional salvage therapy for extended periods of time with
the potential of delaying disease progression [11].
QoL is a multidimensional construct that includes
physical, social, psychological and functional domains at
the very least. A growing consensus among health care
providers and researchers is that treatment efficacy
should be judged by effects on both quantity and quality
of life. This has led to the inclusion of QoL assessmenttd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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traditional endpoints of tumor response and survival.
QoL measurements provide information about the im-
pact of the disease and its treatment on multiple patient
parameters and can aid physicians in selecting and man-
aging antineoplastic and supportive therapy [10].
Baseline or pretreatment QoL has been shown to be a
prognostic indicator in ovarian cancer in three previ-
ously published studies [12-14]. However, to the best of
our knowledge, there is no study in the literature investi-
gating the prognostic impact of changes in QoL scores
on survival in ovarian cancer, whether this is assessed at
the time of initial cancer diagnosis or following disease
relapse. In the current study, we investigated whether
pretreatment QoL parameters as well as changes in
these same QoL scores from baseline to 3 months post-
initiation of therapy could predict survival in patients
with ovarian cancer. This study builds upon our previ-
ous work in this area investigating the relationship be-
tween changes in QoL and survival in other types of
cancers [15,16].Methods
Study population
We examined 137 histologically confirmed ovarian can-
cer patients treated at Cancer Treatment Centers of
AmericaW at Midwestern (MRMC) and Southwestern
(SRMC) Regional Medical Centers between Jan 2001
and Dec 2009 who had QoL data available at both base-
line and 3-month follow-up. The inclusion criteria for
participation in this study were a histological diagnosis
of ovarian cancer and the ability to read English. Patients
with all stages of ovarian cancer were eligible for the
study. Patients were excluded if they were unable to give
informed consent or were unable to understand or co-
operate with study conditions.
A trained clinical coordinator was responsible for deter-
mining eligibility, describing the study, and obtaining in-
formed consent. All patients were assured that refusal to
participate would not affect their future care in any way.
Patients who chose to participate were presented with the
questionnaire at their initial visit and instructed to return
their completed questionnaires to the clinical coordinator
within 24 hours. Thus, patients completed baseline ques-
tionnaires prior to receiving therapy at our facility. Follow-
ing the completion of the baseline questionnaire, all
patients were treated with an integrative model combining
surgery, radiation and chemotherapy as appropriate, plus
complementary therapy consisting primarily of nutritional,
psychosocial, and spiritual support, naturopathic supple-
ments, pain management, and physical therapy/rehabilita-
tion. Patients completed the questionnaire again after a
follow-up period of 3 months.Additional patient data recorded for this study was age
at presentation (current age), stage of disease at diagno-
sis and prior treatment history (previously treated versus
newly diagnosed). The only follow-up information re-
quired was the date of death or the date of last contact/
last known to be alive, obtained from the tumor registries
at Midwestern and Southwestern Regional Medical Cen-
ters. This study was approved by the Institutional Review
Board at Cancer Treatment Centers of AmericaW.
QoL assessment
QoL was assessed using the European Organization for
the Research and Treatment of Cancer Quality of Life
Questionnaire (QLQ-C30), which emphasizes a patient’s
capacity to fulfill the activities of daily living. The QLQ-
C30 is a 30-item cancer specific questionnaire that
incorporates five functioning scales (physical, role,
cognition, emotional, and social), eight symptom scales
(fatigue, pain, and nausea/vomiting, dyspnea, insomnia,
loss of appetite, constipation, diarrhea), financial well-
being scale and a global scale (based on two items: “how
would you rate your overall health during the past week”
and “how would you rate your overall quality of life during
the past week”). The raw scores are linearly transformed
to give standard scores in the range of 0–100 for each of
the functioning and symptom scales. Higher scores in the
global and functioning scales and lower scores in the
symptom scales indicate better QoL. A difference of 5–10
points in the scores represents a small change, 10–20
points a moderate change and greater than 20 points a
large, clinically significant change from the patient’s per-
spective [17]. This instrument has been extensively tested
for reliability and validity [18-20].
Statistical analysis
Patient survival was the primary end point and defined as
the time interval between the date of first patient visit to
the hospital and the date of death from any cause or the
date of last contact/last known to be alive. Two separate
analyses were performed. First, the relationship between
baseline QoL and patient survival was investigated for 137
patients. Second, the relationship between change in QoL
scores between baseline and 3 months and survival was
assessed for the same patient cohort. Change scores were
calculated by subtracting the baseline scores from the 3-
month QoL scores. The overall survival was calculated
using the Kaplan-Meier method. Clinical and QoL vari-
ables were evaluated using univariate Cox proportional
hazards models to determine which parameters showed
individual prognostic value for survival. Multivariate Cox
proportional hazards models were then performed to
evaluate the joint prognostic significance of all QoL and
clinical factors. Each QLQ-C30 scale was treated as a con-
tinuous variable for the purpose of Cox regression
Table 1 Baseline characteristics of 137 ovarian cancer
patients
Characteristic Categories Number Percent
Age at diagnosis (years) ▪ Mean 51.1
▪ Median 51.0
▪ Range 28-75
Vital status ▪ Dead 49 35.8
▪ Alive 88 64.2
Treatment history ▪ Newly diagnosed 28 20.4
▪ Previously treated 109 79.6
Stage at diagnosis ▪ Stage I 16 11.7
▪ Stage II 15 10.9
▪ Stage III 78 56.9
▪Stage IV 28 20.4
Table 2 Baseline quality of life scores stratified by prior
treatment history
Baseline variable Newly diagnosed Previously treated P







Global 58.9 (29.7) 60.0 (22.7) 0.83
General function
Physical 76.1 (22.2) 76.8 (23.0) 0.89
Role 61.9 (32.9) 68.1 (31.1) 0.34
Emotional 68.4 (26.8) 70.6 (23.0) 0.66
Cognitive 79.1 (25.9) 78.1 (22.1) 0.83
Social 63.6 (33.9) 67.2 (32.7) 0.60
General symptom
Fatigue 42.8 (30.7) 39.3 (27.8) 0.56
Nausea/vomiting 11.3 (23.5) 13.6 (22.2) 0.63
Pain 25.0 (29.2) 29.3 (28.4) 0.47
Dyspnea 17.8 (26.4) 22.3 (28.3) 0.45
Insomnia 33.3 (31.4) 39.7 (34.6) 0.37
Appetite loss 28.5 (41.2) 18.6 (25.0) 0.10
Constipation 15.4 (26.4) 23.8 (29.4) 0.17
Diarrhea 11.9 (24.3) 15.9 (24.6) 0.44
Financial 29.7 (34.3) 34.5 (32.3) 0.49
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was expressed as hazard ratios (HRs) with 95% confidence
intervals (CIs). Changes of 10 or more points on a 0 to100
scale are considered clinically relevant [21], so we present
hazard ratios for a 10-point change on the continuous
QoL variables. An effect was considered to be statistically
significant if the p value was less than or equal to 0.05. All
statistical tests were two sided. All data were analyzed
using IBM SPSS version 20.0 (Chicago, IL, USA).
Cox regression with time-invariant covariates assumes
that the ratio of hazards for any two groups remains
constant in proportion over time. We checked this as-
sumption by first examining log-minus-log plots for the
categorical predictors and then fitting a Cox regression
with a time-varying covariate for each predictor in turn.
Potential multicollinearity was assessed in two steps.
Large values (above 0.75) of Pearson’s correlation coeffi-
cients were used as an initial screen for pairs of QoL
variables. As a second check, the variance inflation fac-
tor was used with the final model to verify that
multicollinearity was not significantly influencing model
coefficients [22,23]. In order to minimize instability of
the final multivariate model resulting from high
multicollinearity, global QoL was evaluated separately
because it is most highly correlated with all other vari-
ables on the QLQ-C30 questionnaire, and also because
it is difficult to interpret and manipulate clinically. Fi-
nally, to assess the possible influence of sample bias on
the results, as well as to investigate the stability of the
model coefficients, we performed a bias-corrected and
accelerated (BCa) bootstrap resampling procedure. We
generated 1000 samples, each the same size as the ori-
ginal data set, by random selection with replacement.
Cox regression was then run separately on these 1000
samples to obtain robust estimates of the standard errors
of coefficients, and hence the p values and 95% BCa CIs
of the model coefficients [24].
Results
Patient characteristics
Table 1 describes the baseline characteristics of our
patient cohort. All newly diagnosed patients received
appropriate de-bulking surgery followed by a platinum-
based chemotherapy. All patients with recurrent disease
received systemic chemotherapy chosen by their attend-
ing physician based on prior treatment history. Table 2
displays the baseline QoL scores across the two categor-
ies of prior treatment history. There were no statistically
significant differences in QoL scores between newly di-
agnosed and previously treated patients.
Table 3 describes the results of univariate Cox re-
gression analysis for baseline patient characteristics.
Treatment history was significantly associated with
survival while age and stage at diagnosis were not.Median overall survival for the entire patient cohort
was 33.5 months (95% CI: 11.5-55.6 months). The
median survival for newly diagnosed and previously
treated disease was 66.4 and 19.6 months respectively,
log-rank p<0.001, which is not surprising given that
previously treated patients had advanced stage/recur-
rent disease at the time of presentation to our
institution.
Table 3 Baseline characteristics and associated HRs for
death
Characteristic HR (95% CI) P
Age at diagnosis (years) used as continuous
variable*
1.05 (0.78 – 1.33) 0.70
Stage at diagnosis (stages I-II as reference) 1.68 (0.83 – 3.39) 0.15
Treatment history (newly diagnosed as
reference)
4.4 (1.9 – 10.0) <0.001
*HRs correspond to a 10-point increment for age.
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Table 4 describes the baseline scores for all dimensions
of EORTC QLQ-C30 instrument. Among the EORTC
QLQ-C30 functioning scales, social functioning had the
lowest (worst) mean score of 66.5 while the highest
(best) mean score of 78.3 was recorded for cognitive
functioning. Among the EORTC QLQ-C30 symptom
scales, nausea/vomiting had the lowest (best) mean score
of 13.1 while the highest (worst) mean score of 40.0 was
recorded for fatigue. Table 4 also displays the results of
univariate and multivariate Cox regression analyses for
each QoL variable. The HRs along with their 95% CIs
for every 10-point increase in all EORTC QLQ-C30
scales are given. On univariate analysis, no baseline QoL
variables were predictive of survival. Before proceedingTable 4 Baseline QoL measures and associated HRs for death
Baseline variable QoL score
mean (SD) HR (95% C
General quality of life
Global 59.7 (24.2) 1.05 (0.93 – 1
General function
Physical 76.6 (22.8) 0.93 (0.79 – 1
Role 66.9 (31.5) 0.99 (0.90 – 1
Emotional 70.1 (23.8) 1.02(0.90 – 1
Cognitive 78.3 (22.8) 0.97 (0.85 – 1
Social 66.5 (32.9) 1.02 (0.93 – 1
General symptom
Fatigue 40.0 (28.4) 1.02 (0.92 – 1
Nausea/vomiting 13.1 (22.4) 1.10 (0.94 – 1
Pain 28.4 (28.5) 1.02 (0.91 – 1
Dyspnea 21.4 (27.9) 1.09 (0.99 – 1
Insomnia 38.4 (34.0) 0.98 (0.89 – 1
Appetite loss 20.6 (29.1) 0.98 (0.89 – 1
Constipation 22.1 (28.9) 0.97 (0.87 – 1
Diarrhea 15.0 (24.5) 0.96 (0.83 – 1
Financial 33.5 (32.7) 0.98 (0.89 – 1
• HRs correspond to a 10-point increment for QoL scores.
• 2 sets of multivariate models were constructed: one for global QoL and other for
• Multivariate model (for general function and symptom variables combined) adjust
• Multivariate model for global QoL adjusted for prior treatment history.with multivariate analysis, we checked the bivariate
Pearson’s correlation among the QoL variables to screen
for observable multicollinearity. All correlation coeffi-
cients were smaller than the pre-decided cut-off level of
r=0.75. As a result, all QoL variables were considered in
the multivariate analysis. On multivariate analysis, no
QoL function or symptom variable was found to be sta-
tistically significantly associated with survival. A separate
multivariate model was run for global QoL after
adjusting for prior treatment history. Global QoL was
not found to be significantly associated with survival.
VIF values for baseline QoL variables ranged from 1.1
(diarrhea) to 4.3 (fatigue), none of which indicates a sig-
nificant problem with multicollinearity [22,23]. There
was no evidence of non-proportional hazards in the
multivariate models presented.
In order to further investigate the stability of the clas-
sical multivariate Cox models reported in Table 4, we
conducted a bootstrap resampling procedure based on
1000 samples. The bootstrap estimates of the multivariate
HRs along with corresponding p values and 95% BCa CIs
are provided in Table 5. We found no significant differ-
ences in regression coefficients and their corresponding p
values between the classical Cox regression and bootstrap
Cox regression models.Univariate Multivariate
I) P HR (95% CI) P
.17) 0.45 1.07 (0.94 – 1.19) 0.29
.06) 0.27 1.07 (0.80 – 1.35) 0.63
.07) 0.76 0.91(0.75 – 1.08) 0.30
.14) 0.76 1.07 (0.88 – 1.27) 0.48
.09) 0.66 0.91 (0.71 – 1.11) 0.38
.11) 0.71 1.02 (0.88 – 1.17) 0.76
.12) 0.76 1.11 (0.87 – 1.35) 0.38
.25) 0.21 1.16 (0.97 – 1.35) 0.10
.13) 0.70 0.99 (0.83 – 1.15) 0.90
.18) 0.07 1.10 (0.92 – 1.27) 0.28
.07) 0.67 0.90 (0.78 – 1.02) 0.09
.07) 0.65 0.90 (0.75 – 1.05) 0.19
.07) 0.55 0.94 (0.80 – 1.08) 0.38
.09) 0.58 0.88 (0.72 – 1.04) 0.14
.06) 0.58 0.98 (0.86 – 1.09) 0.68
all general function and symptom variables combined.
ed for prior treatment history and all baseline QoL variables.
Table 5 Bootstrap multivariate HRs for baseline QoL
measures
Baseline variable HR (BCa 95% CI) P
General quality of life
Global 1.07 (0.93 – 1.24) 0.32
General function
Physical 1.07 (0.67 – 1.58) 0.65
Role 0.91(0.64 – 1.15) 0.42
Emotional 1.07 (0.71 – 1.53) 0.53
Cognitive 0.91 (0.65 – 1.13) 0.43
Social 1.02 (0.80 – 1.30) 0.80
General symptom
Fatigue 1.01 (0.75 – 1.73) 0.50
Nausea/vomiting 1.16 (0.64 – 1.59) 0.29
Pain 0.99 (0.69 – 1.23) 0.92
Dyspnea 1.10 (0.83 – 1.42) 0.39
Insomnia 0.90 (0.74 – 1.01) 0.15
Appetite loss 0.90 (0.64 – 1.08) 0.28
Constipation 0.94 (0.72 – 1.12) 0.43
Diarrhea 0.88 (0.58 – 1.11) 0.31
Financial 0.98 (0.75 – 1.20) 0.75
• HRs correspond to a 10-point increment for QoL scores.
• 2 sets of multivariate models were constructed: one for global QoL and other
for all general function and symptom variables combined.
• Multivariate model (for general function and symptom variables combined)
adjusted for prior treatment history and all baseline QoL variables.
• Multivariate model for global QoL adjusted for prior treatment history.
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Table 6 describes the change in scores from baseline to
3 months for all dimensions of EORTC QLQ-C30 in-
strument. On average, they were small. Table 6 also dis-
plays the results of univariate and multivariate Cox
regression analyses for change in QoL scores. On univar-
iate analysis, the only QoL scale that was significantly
predictive of survival was global function. Before pro-
ceeding with multivariate analysis, we checked the bi-
variate Pearson’s correlation among the change scores to
screen for observable multicollinearity. All correlation
coefficients were smaller than the pre-decided cut-off
level of r=0.75. As a result, all QoL change variables
were considered in the multivariate analysis. On multi-
variate analysis, change variables that were significantly
predictive of survival were appetite loss and constipa-
tion. The corresponding HRs for 10-point increase (de-
terioration) in appetite loss and constipation scales were
1.20 (95% CI: 1.06 to 1.35; p=0.005) and 1.13 (95% CI:
1.02 to 1.24; p=0.02) respectively. A separate multivariate
model was run for change in global QoL after adjusting
for prior treatment history. Every 10-point increase (im-
provement) in global function from baseline to 3 monthswas associated with a 10% decreased risk of death
(HR=0.90; 95% CI: 0.81 to 0.99, p=0.03). VIF values for
change in QoL variables ranged from 1.2 (change in diar-
rhea) to 3.9 (change in fatigue), none of which indicates a
significant problem with multicollinearity. There was no
evidence of non-proportional hazards in the multivariate
models presented.
In order to further investigate the stability of the clas-
sical multivariate Cox models reported in Table 6, we
conducted a bootstrap resampling procedure based on
1000 samples. We found no significant differences in re-
gression coefficients and their corresponding p values
between the classical Cox regression and bootstrap Cox
regression models except for the constipation symptom
which changed from being statistically significant in the
classical model to being marginally significant in the
bootstrap model (results not shown in the interest of
space).
We decided to explore the data further by conducting
separate multivariate analysis for previously treated pa-
tients. Similar to what we observed in the total sample
above, improvement in appetite, constipation and global
health scores during the first 3 months of treatment was
significantly associated with improved survival time in
previously treated patients.
Discussion
Women diagnosed with ovarian cancer often receive
therapy over extended periods of time with multiple
treatment regimens. Both the acute and chronic effects
of the disease and its treatment are associated with sig-
nificant side-effects that can adversely impact QoL [25].
And while it is expected that QoL of patients will influ-
ence survival, identifying the most important factors in
ovarian cancer given its heterogeneity with respect to
biology, natural history, and multidisciplinary manage-
ment is a daunting challenge. In fact, it might be
expected that it would be easier to uncover QoL ele-
ments associated with survival by investigating parame-
ters that are affected, positively or negatively, as a result
of therapy. Therefore, the goal of this study was to
evaluate the association between changes in QoL during
treatment and overall survival in patients with either
newly diagnosed or newly-relapsed ovarian cancer.
We found that significant changes in appetite and con-
stipation symptoms, and in global QoL status within 3 -
months of beginning treatment were predictive of
survival time. This is distinct from previous studies
wherein association between baseline QoL and survival
was explored in ovarian cancer [12-14]. In the study by
Carey et al. in advanced ovarian cancer, baseline global
QoL EORTC QLQ-C30 score was found to be an
independent predictor for both progression-free and
overall survival. Baseline EORTC QLQ-C30 cognitive
Table 6 Change in QoL measures and associated HRs for death
Change variable QoL change
mean (SD)
Univariate Multivariate
HR (95% CI) P HR (95% CI) P
General quality of life
Global −0.5 (31.1) 0.89 (0.81 – 0.98) 0.01* 0.90 (0.81 – 0.99) 0.03*
General function
Physical −1.2 (25.6) 1.0 (0.90 – 1.10) 0.99 1.03 (0.82 – 1.23) 0.79
Role 0.0 (36.6) 0.98 (0.92 – 1.05) 0.67 1.11 (0.95 – 1.28) 0.18
Emotional 1.0 (32.2) 0.97 (0.88 – 1.06) 0.48 0.94 (0.78 – 1.09) 0.43
Cognitive −1.2 (31.2) 1.02 (0.93 – 1.10) 0.69 1.18 (0.89 – 1.33) 0.23
Social −0.9 (39.9) 0.97(0.91 – 1.03) 0.36 0.90 (0.79 – 1.01) 0.09
General symptom
Fatigue 2.1 (31.0) 1.02 (0.94 – 1.11) 0.58 0.96 (0.73 – 1.19) 0.72
Nausea/vomiting 1.2 (33.1) 1.02 (0.92 – 1.12) 0.69 0.80 (0.75 – 1.03) 0.08
Pain 1.3 (35.4) 1.02 (0.93 – 1.10) 0.71 0.97 (0.83 – 1.11) 0.68
Dyspnea −0.2 (36.0) 0.97 (0.90 – 1.05) 0.50 0.97 (0.85 – 1.10) 0.66
Insomnia −4.6 (38.8) 1.02 (0.95 – 1.09) 0.62 1.08 (0.97 – 1.19) 0.15
Appetite loss 0.9 (41.8) 1.06 (1.0 – 1.12) 0.06 1.20 (1.06 – 1.35) 0.005*
Constipation 1.2 (34.8) 1.06 (0.98 – 1.14) 0.12 1.13 (1.02 – 1.24) 0.02*
Diarrhea −4.3 (28.5) 1.02 (0.91 – 1.13) 0.74 1.07 (0.93 – 1.20) 0.33
Financial 2.4 (39.7) 0.96 (0.90 – 1.03) 0.29 0.88 (0.78 – 1.02) 0.08
• HRs correspond to a 10-point increment for QoL scores.
• 2 sets of multivariate models were constructed: one for global QoL and other for all general function and symptom variables combined.
• Multivariate model (for change in general function and symptom variables combined) adjusted for prior treatment history and all QoL change variables.
• Multivariate model for change in global QoL adjusted for prior treatment history.
• *P <0.05.
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predictor for overall survival. In addition, at 3 months
after completion of chemotherapy, global QoL score,
performance status and grade were significant independ-
ent predictors of overall survival [12]. In a previous
study conducted by our research team, baseline QoL
was evaluated using Ferrans and Powers Quality of Life
Index in 90 ovarian cancer patients. The health and
physical domain was found to be significantly (although
marginally) associated with survival [13]. Finally, in a re-
cently published study by von Gruenigen et al.,
conducted in 399 stage III ovarian cancer patients re-
ceiving adjuvant chemotherapy, QoL was assessed using
the Functional Assessment of Cancer Therapy-General.
Poor physical well-being reported at baseline was found
to be associated with a significantly increased risk of
death [14]. The present study builds on this previous re-
search to explore whether the dynamic effects of therapy
on QoL scores (as opposed to a single baseline assess-
ment) is associated with survival in ovarian cancer
patients.
The results of this study suggest that baseline QoL
should be considered when planning treatment and
regular QoL assessment performed during the course of
treatment in women with ovarian cancer. Moreover,particular attention should be paid to QoL parameters
related to global health, appetite and constipation and,
when indicated, suitable interventions to support these
parameters should be applied. Positive effects on survival
as a consequence of such interventions would go a long
way towards establishing causative relationships between
these specific QoL parameters and disease control.
Unfortunately, while there has been some progress
with respect to the treatment of appetite loss in cancer
patients, clinical effectiveness is inconsistent and unpre-
dictable. And there are at present no effective means to
address more complex QoL factors such as global
health. This challenges the cancer research enterprise to
develop greater understanding of the complex physi-
ology responsible for all aspects of QoL, and to use this
information to develop more effective and predictable
methods to favorably modulate this critical aspect of pa-
tient health and wellness.
Several limitations of this study need to be acknowl-
edged. Our study, because of its retrospective nature, re-
lies on data not collected to test a specific hypothesis.
As a result, we could not control for certain factors in
our analyses that could influence survival such as treat-
ment received, medical co-morbidities, socioeconomic
factors, support system, exercise and educational level.
Gupta et al. Journal of Ovarian Research 2013, 6:17 Page 7 of 8
http://www.ovarianresearch.com/content/6/1/17The patient cohort was limited only to those patients
who were English speakers and therefore is not repre-
sentative of the complete spectrum of ovarian cancer pa-
tients. A majority of our patients had advanced stage
disease at presentation and had failed primary treatment
elsewhere before coming to our hospital. As a result, we
acknowledge that our findings may not be applicable to
newly-diagnosed ovarian cancer patients with limited
stage disease, an issue that needs to be tested in suitable
patient populations.
Moreover, this study does not reveal a causative rela-
tionship between QoL and survival. Rather, patient QoL
was found to act as a surrogate for otherwise undetected
prognostic factors [26]. QoL scores were assessed over a
3-month interval only which may not be sufficient time
for score changes to develop in other QoL parameters
that may be prognostic of survival. We did not control
for the multiple comparisons made in this study, but this
is acceptable for hypothesis-generating studies [27].
This study also has several strengths, including no
missing data on any EORTC QLQ-C30 variables for the
entire study sample; the use of a valid and reliable QoL
instrument; the availability of clinical parameters in
nearly all patients; and availability of mature and reliable
survival data. As is the case for all exploratory retro-
spective studies, the most important outcome that can
be achieved is the development of a hypothesis sug-
gested by the results. As a consequence of this study, we
hypothesize that the parameters of appetite loss, consti-
pation and global health are independent determinants
of survival in ovarian cancer, and should be regularly
assessed and when indicated, targeted for intervention.
Conclusions
This exploratory study provides preliminary evidence to
indicate that ovarian cancer patients whose appetite,
constipation and global health improve within 3 months
of treatment have a significantly increased probability of
survival. Given that QoL is as meaningful as the actual
length of life in patients with advanced ovarian cancer,
these findings should be used in clinical practice to sys-
tematically address QoL-related problems of ovarian
cancer patients throughout their treatment course.
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